Diego Cadavid to present at 3rd Annual ALD Drug Development Summit

We are thrilled that Verge Genomics' CMO Diego Cadavid is presenting at the 3rd Annual ALS Drug Development Summit on May 23rd at 11:30 AM. Diego will share insights on Verge’s groundbreaking proof-of-concept study design to evaluate VRG50635 as a potential novel therapeutic candidate for ALS. Don't miss this opportunity to learn more about VRG50635 and the future of ALS treatment! https://ter.li/qdfuop

Location: Hyatt Regency Boston, 1 Ave de Lafayette, Boston, MA 02111